Quick Answer
Candel Therapeutics, Inc. reported Revenue (ASC 606) of $125.0 thousand for fiscal year 2022.
Candel Therapeutics, Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2022 | $125.0K | +0.0% |
| 2021 | $125.0K | +0.0% |
| 2020 | $125.0K | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2022 | $31.0K | +0.0% | +0.0% |
| June 30, 2022 | $31.0K | +0.0% | +0.0% |
| March 31, 2022 | $31.0K | +0.0% | +0.0% |
| September 30, 2021 | $31.0K | +0.0% | +0.0% |
| June 30, 2021 | $31.0K | +0.0% | +0.0% |
| March 31, 2021 | $31.0K | — | +0.0% |
| September 30, 2020 | $31.0K | — | +0.0% |
| June 30, 2020 | $31.0K | — | — |
- Candel Therapeutics, Inc. showed an increase of +0.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Over the 2020–2022 period, Candel Therapeutics, Inc.’s revenue (asc 606) has grown by 0.0% (from $125.0 thousand to $125.0 thousand).
- The most recent figure is from Candel Therapeutics, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on March 28, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: